SynBioBeta Speaker
Jonas Sandbrink
Sentinel Bio
Entrepreneur-in-Residence
Jonas is an Entrepreneur-in-Residence at Sentinel Bio, where he is building BioTrust: a verified researcher credential for accessing bio-capable AI models. Researchers verify once, and get trusted across providers. Previously, he worked at the UK AI Security Institute, where he founded and built the chemical and biological evaluations program, which informed frontier AI labs model deployments. Later, he led AISI’s Strategic Awareness work to increase government understanding and preparedness for advanced AI capabilities. Before joining the AI Security Institute, he researched synthetic biology and AI biosecurity risks at the University of Oxford, and advised the UK Cabinet Office, Google DeepMind, and the Nuclear Threat Initiative.Jonas holds a PhD from Oxford's Nuffield Department of Medicine, where his interdisciplinary work combined scientific risk assessment, policy analysis, and ethics to examine misuse risks from synthetic virology and AI.
SynBioBeta 2026 Tickets are Live
Confirmed Speakers
Sessions Featuring
Jonas
This Year
•
-
Business of Biology
Synthesis Screening in the Age of Powerful AI
As AI reshapes what's possible in biology, biosecurity needs to keep up. Nucleic acid synthesis screening, which checks what's being ordered and by whom, is one of the field's most important lines of defense. But as AI capabilities advance, the screening infrastructure needs to evolve with them. This panel brings together leaders from the Sequence Biosecurity Risk Consortium, Fourth Eon Bio, SecureDNA, and BioTrust to discuss how sequence and customer screening are adapting to a new threat landscape.
•
-
Business of Biology
Synthesis Screening in the Age of Powerful AI
As AI reshapes what's possible in biology, biosecurity needs to keep up. Nucleic acid synthesis screening, which checks what's being ordered and by whom, is one of the field's most important lines of defense. But as AI capabilities advance, the screening infrastructure needs to evolve with them. This panel brings together leaders from the Sequence Biosecurity Risk Consortium, Fourth Eon Bio, SecureDNA, and BioTrust to discuss how sequence and customer screening are adapting to a new threat landscape.
Session lineup still growing
Featuring
Speaker Coming Soon
•
-
Human Health
From Cells to Patients: Solving the Scale Mismatch in Virtual Biology
Drug discovery often measures biology at the cell level while interventions work at the tissue, organ, or whole-patient scale. This mismatch can make accurate cell-level predictions irrelevant in the clinic. This session dives into strategies to bridge that gap: multiscale modeling that nests single-cell dynamics within organ-level simulations, spatial transcriptomics that preserve context, and surrogate models that translate cell-level outputs into clinical biomarkers. Speakers will ask: how do we ensure virtual biology reflects not just what cells do in isolation, but how biology behaves in the real complexity of patients?
Featuring
Speaker Coming Soon
